Investor relations
Menu
We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics
Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post surgically.
Nasdaq: PRFX
3.35
CHANGE: -25.56%
DAILY VOLUME: 741,708
LAST UPDATE: 12-07-2024 02:00
PainReform CEO Ilan Hadar Interviewed on “The Big Biz Show”
our numbers
Up to
72
hours post-operatively
Phase
3
Clinical Trial
2007
Founded
US
$12B
Post-operative pain treatment overall market
*2017
US
$45B
future post-operative pain treatment overall market
*is expected to reach by the end of 2026
Over
40-45
million procedures in the US per year
press releases
Presentation
03/03/2024
